Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer.

Calcitriol, a regulator of calcium homeostasis with antitumor properties, is degraded by the product of the CYP24A1 gene, which is downregulated in human prostate cancer by unknown mechanisms. We found that CYP24A1 expression is inversely correlated with promoter DNA methylation in prostate cancer cell lines. Treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (DAC) activates CYP24A1 expression in prostate cancer cells. In vitro methylation of the CYP24A1 promoter represses its promoter activity. Furthermore, inhibition of histone deacetylases by trichostatin A (TSA) enhances the expression of CYP24A1 in prostate cancer cells. Quantitative chromatin immunoprecipitation-PCR (ChIP-qPCR) reveals that specific histone modifications are associated with the CYP24A1 promoter region. Treatment with TSA increases H3K9ac and H3K4me2 and simultaneously decreases H3K9me2 at the CYP24A1 promoter. ChIP-qPCR assay reveals that treatment with DAC and TSA increases the recruitment of vitamin D receptor to the CYP24A1 promoter. Reverse transcriptase-PCR analysis of paired human prostate samples revealed that CYP24A1 expression is downregulated in prostate malignant lesions compared with adjacent histologically benign lesions. Bisulfite pyrosequencing shows that CYP24A1 gene is hypermethylated in malignant lesions compared with matched benign lesions. Our findings indicate that repression of CYP24A1 gene expression in human prostate cancer cells is mediated in part by promoter DNA methylation and repressive histone modifications.

[1]  T. Down,et al.  Placenta-specific Methylation of the Vitamin D 24-Hydroxylase Gene , 2009, Journal of Biological Chemistry.

[2]  H. Cedar,et al.  Linking DNA methylation and histone modification: patterns and paradigms , 2009, Nature Reviews Genetics.

[3]  R. Dahiya,et al.  DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines , 2008, International journal of cancer.

[4]  Tai-Chi Chen.  25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate. , 2008, Anticancer research.

[5]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[6]  K. Tashiro,et al.  Role of distal upstream sequence in vitamin D-induced expression of human CYP24 gene. , 2007, Biochemical and biophysical research communications.

[7]  N. Nowak,et al.  Epigenetic Silencing of CYP24 in Tumor-derived Endothelial Cells Contributes to Selective Growth Inhibition by Calcitriol* , 2007, Journal of Biological Chemistry.

[8]  K. Odunsi,et al.  DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. , 2007, Cancer immunity.

[9]  M. Nichols,et al.  CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer , 2006, International journal of cancer.

[10]  M. Fraga,et al.  A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. , 2006, Cancer research.

[11]  Wei-dong Yu,et al.  Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. , 2006, Cancer research.

[12]  J. Schmid,et al.  Selective inhibitors of vitamin D metabolism--new concepts and perspectives. , 2006, Anticancer research.

[13]  M. Fakih,et al.  Vitamin D compounds: clinical development as cancer therapy and prevention agents. , 2006, Anticancer research.

[14]  S. Yee,et al.  Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  Glenville Jones,et al.  Evidence for the activation of 1α-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: Delineation of pathways involving 1α,24-dihydroxyvitamin D2 and 1α,25-dihydroxyvitamin D2 , 2006 .

[16]  Cyrus Martin,et al.  The diverse functions of histone lysine methylation , 2005, Nature Reviews Molecular Cell Biology.

[17]  D. Peehl,et al.  Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity , 2005, Molecular and Cellular Endocrinology.

[18]  C. Carlberg,et al.  Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-Dihydroxyvitamin D3. , 2005, Journal of molecular biology.

[19]  H. Cross,et al.  Epigenetic regulation of Vitamin D hydroxylase expression and activity in normal and malignant human prostate cells , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  Glenville Jones,et al.  Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. , 2005, Endocrinology.

[21]  Xiaoan Ruan,et al.  Expression of VDR and CYP24A1 mRNA in human tumors , 2005, Cancer Chemotherapy and Pharmacology.

[22]  E. Meese,et al.  Analysis of the vitamin D system in basal cell carcinomas (BCCs) , 2004, Laboratory Investigation.

[23]  J. Reichrath,et al.  Analysis of the vitamin D system in cutaneous squamous cell carcinomas , 2004, Journal of cutaneous pathology.

[24]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[25]  T. Shinki,et al.  Mechanisms for the reduction of 24,25‐dihydroxyvitamin D3 levels and bone mass in 24‐hydroxylase transgenic rats , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  J. Issa,et al.  Critical Role of Histone Methylation in Tumor Suppressor Gene Silencing in Colorectal Cancer , 2003, Molecular and Cellular Biology.

[27]  J. Herman,et al.  Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. , 2003, Cancer cell.

[28]  J. Reichrath,et al.  Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[29]  H. Ide,et al.  Extensive methylation of CpG island of CYP24 gene in osteoblastic ROS17/2.8 cells. , 2002, Nucleic acids research. Supplement.

[30]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[31]  T. Shinki,et al.  Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. , 2002, Biochemical and biophysical research communications.

[32]  W. Nelson,et al.  Methyl-CpG Binding Domain Protein 2 Represses Transcription from Hypermethylated π-Class Glutathione S-Transferase Gene Promoters in Hepatocellular Carcinoma Cells* , 2002, The Journal of Biological Chemistry.

[33]  C. Handschin,et al.  NUBIScan, an in silico approach for prediction of nuclear receptor response elements. , 2002, Molecular endocrinology.

[34]  D. Reinberg,et al.  Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. , 2001, Genes & development.

[35]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[36]  H. Cross,et al.  25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. , 2001, Biochemical and biophysical research communications.

[37]  I. Schuster,et al.  Selective inhibitors of CYP24: mechanistic tools to explore vitamin D metabolism in human keratinocytes , 2001, Steroids.

[38]  Luciano Milanesi,et al.  GeneBuilder: interactive in silico prediction of gene structure , 1999, Bioinform..

[39]  J. Strouboulis,et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.

[40]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[41]  M. Haussler,et al.  The vitamin D hormone and its nuclear receptor: molecular actions and disease states. , 1997, The Journal of endocrinology.

[42]  H. DeLuca,et al.  Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. , 1996, Biochemistry.

[43]  M. Holick,et al.  Vitamin D and bone health. , 1996, The Journal of nutrition.

[44]  H. DeLuca,et al.  Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. , 1995, Biochimica et biophysica acta.

[45]  J. Foekens,et al.  Vitamin D: A modulator of cell proliferation and differentiation , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[46]  R. Ray,et al.  Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. , 1989, The Biochemical journal.

[47]  H. DeLuca,et al.  Vitamin D: recent advances. , 1983, Annual review of biochemistry.